As the aforementioned transient induction of melanoma tumor antigens by BRAF and MEK inhibitors, increase in intratumoral T cells resulted from MAPK pathway inhibition was also lost at the time of progression on therapy [35]. The gene discussed is MAP2K7; the disease is melanoma.